HYPOTHESIS: TETRACYCLINES FOR SEVERE COVID-19 – THE PERFECT REPURPOSING
CANDIDATE?
- Jose Garrido-Mesa,
- Kate Adams,
- Julio Galvez,
- Natividad Garrido Mesa
Kate Adams
School of Health, Sport and Bioscience. University of East Lodon. E15 4LZ.
Author ProfileNatividad Garrido Mesa
School of Health, Sport and Bioscience. University of East Lodon. E15 4LZ.
Author ProfileAbstract
We would like to draw attention to the potential of immunomodulatory
tetracyclines for severe COVID-19. The COVID-19 pandemic is having a
devastating impact on developing countries. A successful approach to
manage the scarcity of cost-effective therapies worldwide is drug
repurposing. Predictions of direct anti-viral activity of tetracyclines
against SARS-CoV2 have been confirmed experimentally. Furthermore, their
effectiveness in experimental ARDS has been proven extensively,
counteracting the overt inflammatory reaction and fibrosis sequelae due
to a synergic combination of pharmacological activities. Finally, a few
clinical reports have confirmed their potentiall in COVID-19 patients,
encouraging the development of this novel indication. We believe that
the benefits of their multi-target pharmacology and their safety profile
place immunomodulatory tetracyclines as gold repurposing candidates for
COVID-19.